High-Throughput/High Content Imaging Screen Identifies Novel Small Molecule Inhibitors and Immunoproteasomes as Therapeutic Targets for Chordoma
Chordomas account for approximately 1–4% of all malignant bone tumors and 20% of primary tumors of the spinal column. It is a rare disease, with an incidence estimated to be approximately 1 per 1,000,000 people. The underlying causative mechanism of chordoma is unknown, which makes it challenging to...
Main Authors: | Amrendra K. Ajay, Philip Chu, Poojan Patel, Christa Deban, Chitran Roychowdhury, Radhika Heda, Ahmad Halawi, Anis Saad, Nour Younis, Hao Zhang, Xiuju Jiang, Mahmoud Nasr, Li-Li Hsiao, Gang Lin, Jamil R. Azzi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/4/1274 |
Similar Items
-
Clinical and histopathological characteristics and differential diagnosis of chordomas
by: Tuba Canpolat, et al.
Published: (2016-12-01) -
Sacral chordoma with metastatic dissemination in a child: case report
by: Camile Cremonese Gobbo, et al.
Published: (2022-09-01) -
Chordoma: Excellent Response to Radiotherapy in Combination With Hyperthermia
by: Mohammad Reza Barzegartahamtan, et al.
Published: (2023-12-01) -
Chordoma—Current Understanding and Modern Treatment Paradigms
by: Sean M. Barber, et al.
Published: (2021-03-01) -
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
by: Jeffrey I. Traylor, et al.
Published: (2021-05-01)